Pergamon

Bioorganic & Medicinal Chemistry Letters 9 (1999) 1385-1390

BIOORGANIC & MEDICINAL CHEMISTRY LETYERS

EFFICIENT INHIBITION OF MUSCLE AND LIVER GLYCOGEN PHOSPHORYLASES BY A NEW GLUCOPYRANOSYLIDENE-SPIROTHIOHYDANTOIN
Erz~bet ~)sz', L/iszl6 Som~iiP', Liszl6 SzillgyP', Liszl6 Kovlcs', Tibor Docsa b, B~la T6th b, Pil Gergely b

"Department of Organic Chemistry, Lajos Kossuth University, P.O.B. 20., H-4010, Debrecen, Hungary, bDepartment of Medical Chemistry, UniversityMedical School of Debrecen, 1-1-4026,Debrecen, Hungary

Received 8 March 1999; accepted 2 April 1999

A l ~ m e t : Reaction of C-(1-bromo-l-deoxy-13-D-glueopyrmlosyl)fo~ 2 with thioeyaa~ ions was the key step of a short s y n t ~ of D-glucopyraaosylidene-spiro-thiobydaatoin 7 which proved to be a potent inl~'bitor of nmsele ~ glycogen pho$pbolyla.~. © 1999Elsevier ScienceLtd. All fightsreserved.

Non-insulin dependent diabetes mellitus (NIDDM or Type 11 diabetes) can be controlled mainly by dietary regulation and with the use of hypoglyeaemie agents) Blood glucose c o ~ n , however, cannot be regulated

very efficiently by these methods. Therefore, considerable efforts have been made to understand the action and elicit intn'hition, using glucose derivatives, of glycogen phosphozylase (GP) the main regulatory enzyme of blood sugar level 2"6The most potenl inhibitor, known to date, of muscle GPb is a glucopyraaosylklene-spiro-hydantoin derivative 7 5 (K~= 3.1 + 0.2 DAM),for which several multistep syntheses have been publisbed. 2~'7 Apart from tbe lengthiness of

these synthetic sequemes, unfavourable stereoseleetivity as well as aaotmdzatiom in the ~

strongly

decrease the stereoehannicadetfei~aey of this compound's production. It is tlm~fore unlikely that these syntheses will
be useful for the preparation of the large amounts of this inhibitor3 required for more elaborate biological

investigations. Obviously, any readily available potent inh~3~itorcould lactate deeper ~
of action of GP and validate the concept of its inl~ition as potential therapy of diabetes. Herein we report the synthesis of a glucopyranosylMene-spiro-thiobydantoin (7) ~

of the mechanism

on a six step, simple, highly

ehemo-, regio-, and stereoseleetive procedure starting from o-glucose and the kinetic ~

demonstrating effaeient

"Authorsto whom correspondeaceshouldbe addressed- e-mail: somsak~igris.klte.hu; Iszilagyi~tigris.klte.hu;
tel: (+36)52-512-900;fax: (+36)52-453-836.

0960-894X/99/$ - see front matter © 1999 Elsevier Science Ltd. All rights reserved. PII: S0960-894X(99)00192-4

1386

E. Osz et a l . / Bioorg. Med. Chem. Lett. 9 (1999) 1385-1390

in/£oition of muscle and liver glycogen phosphoryiases by this compound.

Chemistry

1-Bromo-l-deoxy-~-D-glucopyrm~syl cyanide 1,s readily available by radicai-rr~xiiated bromip.ation9 of the corresponding acetylated [3-D-glucopyranosyl cyanide, ~° was transformed into the C-(1-bromo-l-deoxy-[3-Dghcopyranosyl)fonmnfide 211 by TiCh mediated partial hydrolysis. 12°13Ring closure of 2 was effected by AgOCN in dry nitromethane whereby formation of a mixture of spiro-hydantoins 4 H and 811 (ratio 1 : 10 by ~H NMR) was observed. Transformation of 2 with AgSCN or KSCN in dry nitromethane gave 611 as a single anomer. In each reaction a small amount of 3 ~1 could be isolated as an unavoidable by-product. Deprotection of 4, 6, and 8 under Zemplen.-corlditions a,~-orded 5, 7 '7,11and 9, 7 respectively.

OAc

OR 1 ii or iii =

Acoc A
· ~2

O

O,t ol ~ ' "
Rz

I:K)~NH

8

+

'X~RO

5

O 10 O

1 R 1 = CN, R2 ffi Br R 1 =CONH 2, R2ffi Br 3 R I = C O N H 2'R 2 = O H

iC4
iC6

R=Ac, X=O
5 R=H, X=O

iC

~ R=Ac R=H

RffiAc, XffiS
7 R=H, X=S

Scheme: i TiCh, H20, AcOH, 0 °C-r. t.; ii AgOCN (4 eq) dry CH3NO2, 80 °C; iii AgSCN (4 eq) or KSCN (2 eXl), dry CH3NO2, 80 °C; iv NaOMe, McOH, r.t.

Constitution of the spiro-hydantoins was established using NMR methods, lla4 Compounds 4-9 showed characteristic ~H and 13C resonances expected for the (thio)hydantoin rings t4-16 and corresponding long-range 13C/IH correlations ~ idclltiflcd in the HMBC spectra. The pyral~sc 1 ~ conforn'gRio115were deduced from 3fire1

vahes as 4C1 for each derivative and the C-6 configurations dete~ihed as S for 6 and 7 and R for 8 on the basis of 33H.5,C.10values. H The 1H and 13C NMR spectra for 5 and 9 were identical with the reported ones. 7 The configurational agqi~ were supported by mHchemical shift rules recently ~ l b l i s l ~
13 for spiro-hydantoms.

Kinetic Studies

Glycogen phosphorylas¢ b was isolated from rabbit skeletal muscle according to the trothed of Fischer and Krebs2~ with the difference of using 2-ng~aptocthanol instead of L-oysteme. Phosphorylas¢ kinas¢ was prepared from rabbit skeletal nmscle22 for converting muscle phosphorylase b into phosphorylase a as descrfl~ in.23 Hepatic phosphorylase

E. Osz et al. /Bioorg. Med. Chem. Lett. 9 (1999) 1385-1390

1387

b and a were ~

from rat livers according to the reported method) 4 For the preparation of liver phosphorylase a

ghw,agon (100 og/kg) was injected intravenonsly 30 sec before cutting tbe jugular veins and 50 mM NaF was added to the buffers to keep the enzyme in the phosphorylated form in all subsequent steps. Liver phosphorylase b was prepared from non-glucagonized rats without NaF addition to the buffers. Phosphorylase activities were assayed in the direction of glycogen synthesis at 30°C with 10 ~tg/ml enzyrae, 1% glycogen, in the absence of AMP (muscle or liver phosphorylase a) or in the presence of AMP (1 mM AMP for muscle and 2 mM AMP for liver phosphorylase b) with or without hydantoim 5, 7, and 9 in 50 mM trietlumolamim/HCl (pH 6.8) buffer, 100 mM KCI, 1 mM dithiothreitol and 1 mM EDTA. The kinetic studies w ~ performed as described previously25 with the exception that higher Dglucose 1-phosphate concentrations were used for the assay of liver phosphorylases as suggested by Stalrmns and
H e r s . 26

Inhibition of liver phosphorylase b by compound 7 according to Linewcaver-Burk is shown in Fig. 1. The

inlu'bitor constant for 7 calculated from a Dixon plot (Fig. 2) is K~= 7 ~M.

Figure 1
4OO

Figure 2

30 30O

20

20O
10O

lO

0 -0.02 0 0.02 0.04 0.06 0.08 0 20 40

60

1/[D-glucose 1-phosphate], m M

[spiro-thiohydantoin 7], gM

Figure 1. Double-reciprocal plot for liver phosphorylase b at constant concentrations of AMP (1
mM) and glycogen (1%), and varying concentrations of D-glucose 1-phosphate. Concentrations of 7 were as follows: 0 (O), 10 (ll), 20 (V), 30 (+), 40 (A) and 50 laM (0). The plots were analysed by a non-linear data-analysis program. 27

Figure 2. Determination of Ki value by replotting the slopes in Figure 1 against the inlu'bitor
concentrations. 28 The means of standard errors for all calculated kinetic parameters averaged to less than 10%.

1388

E. Osz et al./Bioorg. Med. Chem. Lett. 9 (1999) 1385-1390

Inl~itor constants (K,) of thiohydantoin 7 for muscle and liver phosphorylases are summarized in Table 1. For comparison, inh~itor constants of hydantions 5 and 9 determined with muscle and liver phosphorylases are also presented together with those published previously2'7 for muscle phosphorylase b. Compound 5 proved to be a potent inht~tor as descn'bed before,7 the epimeric 9 was, however, found to be more effective than
reported. 2 Liver phosphorylase a was only slightly inhl%ited by 9. It can be concluded that phosphorylase a

activities (assays in the absence of AMP) are less sensitive to the inhibitory action of compounds 5 or 7.

Table 1. lnhl"o~or eonstans (Ki [}~[]) of spiro-(thio)hydantoins 5, 7, and 9 for muscle and liver phosphorylases

Type ofphosphorylase Liver phosphorylase b Liver phosphorylase a Muscle phosphorylase b

5 12.8±1.1 16.5±1.3 4.2±0.4 (3.1±0.27 )

7 7.0±1.0 29.8±2.9 5.1±0.5

9 ~d.* 2050±180 105±9 (3202)

Muscle phosphorylase a *not determined

26.0±2.4

10.9±1.0

n.d.*

Conclusion

The newly synthesized spiro-thiohydantoinderivative of D-glucose (7) was found to be a very potent inhfl~r of nmscle and liver glycogen phosphorylases b and a. The inh/bitory effickncy of 7 is comparable to that of the best substange (5) known for this purpose to date. Due to the minor ditferew.e inthe smLeaa~ of 5 and 7 the important hydrogen bond between N7-H and His377, detected by X-ray crystallographyfor musele GPb--5 c o m p l ~ 29 I I ~ alSO exist in the enzyme-7 complexes resulting in similar ~ n s . Purified liver phosphorytases were used for the f r a

thne in our experknents implyinga potential role of inhl]~itorsin the hetmtic glycogen metaboli.~a.

Acknowledgements

This work was supported by the Hungarisn National Science Folmdation (OTKA T 19339, T 23814, T26541), the M'mt,~tryof F_Auca~n (FKFP 500/1997, FKFP 784/1997), the Nfmistryof Health (ETr T-02/150/98), the Z s i ~ n d Diabetes Foundation of the Hungarian Aca,Lemyof Sciences, and in part by OMFB (F-7/96) in Hungary and Lc M'm~,~'e des ~ I~mmgi~s (France). We thank dr. Z. Dinya for tbe FAB-MS mms~eir~s.

E. Osz et al. / Bioorg. Med. Chem. Lett. 9 (1999) 1385-1390

1389

References and Notes

1.

2. 3.
4.

.
.

7.
o

9. 10. 11.

Hcngesh, E. J. Drugs Affecting Sugar Metabolism. In= Principles of Medicinal Chemistry; Foye, W. O.; Lemke, T. L.; Williams, D. A.Eds.; William.qand Wilki~q:Baltimore, 1995; pp 581-600. Kr011e, T. M.; de la Fnente, C.; Watson, IC A.; Gregoriou, M.; John,son, L. N.; Tsitsanou, ICE.; Zographos, S. E.; Oikonomak0s, N. G.; Fleet, G. W. J. Synlett 1997, 211-213. de la Fuente, C.; Krfille, T. M.; Watson, IC A.; Gregoriou, M.; Johnson, L. N.; Tsitsanou, ICE.; Zographos, S. E.; O~onomakos, N. G.; Fleet, G. W. J. Synlett 1997, 485-487. KrOlle, T. M.; de la Fuente, C.; Pickering, L.; Aplin, R. T.; Tsitsanou, ICE.; Zographos, S. E.; Oikonomakos, N. G.; Nash, R. J.; Griffiths, R. C.; Fleet, G. W. J. Tetrahedron: Asymmetry 1997, 8, 38073820. Heightman, T. D.; Vasella, A.; Tsitsanot~ ICE.; Zographos, S. E.; Skamnaki, V. T.; Oikonomakos, N. G.; Heir. Chim. Acta 1998, 81, 853- 864. Agasimundin, Y. S.; Mum~r, M. W.; Hosmane, R. S. Bioorg. Med. Chem. 1998, 6, 911-923. Bichard, C. J. F.; Mitchell, E. P.; Wormald, M. R.; Watson, IC A.; Johnson, L. N.; Zographos, S. E.; Koutra, D. D.; Oikonomakos, N. G.; Fleet, G. W. J. Tetrahedron Left. 1995, 36, 2145-2148. Lichtenthaler, F. W.; Jarglis, P.Angew. Chem., Int. Ed. Engl. 1982, 21,625-626. Soms~Lk,L.; Ferriei, R. J. Adv. Carbohydr. Chem. Bioehem. 1991, 49, 37-92. Myers, R. W.; Lee, Y. C. Carbohydr. Res. 1986, 154, 145-163. Characterization of the new compounds (isolated yields are given): 2 yield: 68 %; nap: 119-1210C, [c~]D+124 (c 1.09, CHCI3), IH-N-MR (CDCI3) 5 6.50 (1H, s, NI-I2), 6.02 (IH, s, NH2), 5.44 (1H, t, J= 9.4 Hz, H-3), 5.20 (1H, d, J = 9.4 Hz, H-2), 5.16 (lI-I, t, J = 9.4 I-Iz, H-4), 4.33-4.22 (3H, m, H-5,6,63; ~3C-NMR(CDCI3) 5 166.9 (CONH2, 3ja.2.co0~m)= 1.5 I-Iz), 92.7 (C-l), 74.3, 71.6, 69.6, 66.7 (C-2 to C-5), 60.7 (C-6); AnaL: calcd, for CisH20NO~0Br (454.24): C 39.6, H 4.43, N 3.08, Br 17.59; found: C 38.74, H 4.74, N 3.21, Br 17.17. 3 yield: 19 %; rap: 175-1770C; [c~]v+35 (c 1.35, acetone); ~H-NMR(CD3OD) ~ 5.48 (lI-I, dd, J = 9.9, 9.5 I42, H-3), 5.29 (1H, d, J = 9.9 Hz, H-2), 5.15 (1H, dd, J= 10.1, 9.5 Hz, H.4), 4.32 (lI-I, dd, J= 12.2, 5.2 Hz, H-6), 4.25 (1H, ddd, or = 10.1, 5.2, 2.3 Hz, H-5), 4.16 (1H, dd, or -- 12.2, 2.3 Hz, H-63; ~3C-NMR (CD3OD) 8 172.5 (CONH2,3Ja.2.coom2)~ 1 Hz), 95.6 (C-l), 72.7, 72.5, 70.6, 70.1 (C-2 to C-5), 63.7 (C6); High resolution MS: calcd, for C15H22NOH I'M+H]+ 392.11926, found 392.11933, A (mmu) 0.06. 4 yield: 4 %; oil; [ct]D+18 (c 1.01, CHCI3); ~H-HMR(CDCI3): 5 8.14 (lI-I, s, H-9), 6.23 (1H, s, H-7), 5.92 (1H, quasi t, or= 10.1, 9.8 Hz, H-4), 5.32 (1H, d, or= 10.1 Hz, H-5), 5.2 (lI-I, quasi t, J= 10.2, 9.8 H_z,H3), 4.7 (1H, ddd, or= 10.2, 4.1, 2.1 H_z,H-2), 4.29 (1H, dd, or= 12.7, 4.1 Hz, CH2), 4.13 (1H, dd, or= 12.7, 2.1 Hz, CH2); ~3C-NMR(CDCI3): 8 168.9 (C-10), 154.6 (C-8), 86.4 (C-6), 71.5, 70.6, 70.1, 67.8 (C-2 to C-5), 61.8 (CH2); High resolution MS: calcd, for C16H21N2On [M+H]+ 417.1139, found 417.1143. 6 yield 57 %; rap 223-2240C; [ct]i) +2 (c 2.12, CHC13); ~H-N-MR(CDCI3) 8 8.38 (1H, s, H-9), 7.21 (1H, s, H-7), 5.92 (1H, dd, or= 10.1, 9.8 Hz, H-4), 5.34 (lI-I, d, or= 10.1 I-Iz, H-5), 5.21 (1H, quasi t, or= 9.9, 9.8 Hz, H-3), 4.74 (1H, ddd, or= 9.9, 4.2, 2.0 Hz, H-2), 4.29 (1H, dd, or= 12.7, 4.2 I-Iz, CTI2),4.14 (1H, rid, or = 12.7, 2.0 Hz, CH2); 13C-N]V[R(CDCI3)~ 182.1 (C-8), 171.0 (C-10, 3~.5.c.10= 6.1 Hz), 86.8 (C-6), 70.7, 69.8, 69.7, 67.5 (C-2 to C-5), 61.6 (CH2); tSH-NMR (CDCI3, referenced to NI-I4CIas external standard) 130.9 (N-7), 160.5 (N-9); High resolution MS: caicd, for Cl~-I21N2OioS [M+H]+ 433.09167, found 433.09172, A (nnnu) 0.11. 7 yield: 78 %; amorphous product; [Ct]D +19 (C 2.34, CH3OH); IH-N'M]~(CD3OD) ~ 4.23 (1H, ddd, or = 10.0, 5.4, 2.2 Hz, H-2), 4.13 (1H, t , J = 9.6 Hz, H-4), 3.83 (1H, dd, or= 12.2, 2.2 Hz, CH2), 3.68 (1H, dd, or = 12.2, 5.4 Hz, CH2) 3.54 (1H, d, J = 9.6 I-Iz, H-5), 3.37 (1H, dd, or = 10.0, 9.6 Hz, H-3); ~3C-NMR (CD3OD) ~ 185.9 (C-8), 174.6 (C-10, 3ora.5.c.~0 6.3 Hz), 90.7 (C-6), 76.8, 74.4, 74.1, 70.9 (C-2 to C-5), = 62.7 (CH2); High resolution MS: calcd, for CsH~3N206S [M+I-I]÷ 265.04941, found 265.04953, A (mmu) 0.16. 8 yield: 25 %, amorphous product; Icily +29 (c 2.54, CHCI3); IH-NMR (CDCI3): 6 8.98 (IH, s, H-9), 8.3 (lI-I, s, H-7), 5.6 (1H, d, or= 10.2 Hz, H-5), 5.56 (1H, dd, or= 10.2, 9.0 H_z,H-4), 5.26 (lI-I, dd, or= 10.2,

1390

E. Osz et al. / Bioorg. Med. Chem. Lett. 9 (1999) 1385-1390

9.0 Hz, H-3), 4.28 (1H, dd, J = 12.6, 4.4 Hz, CH:), 4.19 (1H, dd, J = 12.6, 2.1 Hz, CHz), 4.03 (1H, ddd, J = 10.2, 4.4, 2.1 Hz, H-2); ~3C-NMR (CDCI3): 6 167.9 (C-10, 3JM.5.C.10 2.8 Hz), 156.8 (C-8), 87.4 (C= 6), 71.8, 71.6, 68.2, 68.0 (C-2 to C-5), 61.9 (CH:). High resolution MS: calcd, for Ct6H21NzOH [M+H]+ 417.1145, found 417.1146, A (mmu) 0.13. 12. BeMiller, J. N.; Yadav, M. P.; Kalabokis, V. N.; Myers, R. W. Carbohydr. Res. 1990, 200, 111-126. 13. 0sz, E.; S6s, E.; Somsdk, L.; Szil~gyi, L.; Dinya Z. Tetrahedron 1997, 53, 5813-5824. 14. NMR data allowed to rule out possible other isomers which could have, theoretically, arisen from nucleophilic attack by the sulfur rather than the nitrogen atom of the thiocyanate ion (B, C) or ring closure by attack of the amide oxygen instead of nitrogen (A, C). The measured ~3C chemical shifts are characteristic m5'16of C=S (182.1 ppm in 6 and 185.9 ppm in 7) and C=O groups (171.0 ppm in 6 and 174.6 ppm in 7) and ~N shifts (6N 130.9 ppm and 160.5 ppm in 6) correspond to ring NHs in hydantoins. 17 In contrast, C=N bonds present in each of the alternative structures A-C would require 6C and 5N values to be in the ranges between 152-166 ppmis and 200-300 ppm, 19 respectively. The only glycosylidene-spirothiohydantoin derivatives which we could locate in the literature are analogues 2° of (+)-hydantocidin charactedsed by lH NMR, IR and MS but not by 13C and 15NNMR data. I-~ --O O I-~ O --O A 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. B O
N HN

C

Sobczyk, K.; Siemion, I. Z. Pol. J. Chem. 1980, 54, 1833-1840. Osz, E.; Szildgyi, L.; Marton J. J. Mol. Struct. 1998, 442, 267-274. Witanowski, M.; Stefaniak, L.; Webb, G. A. Nitrogen NMR Spectroscopy. In: Annual Reports on NMR Spectroscopy; Webb, G. A. Ed.; Academic Press: London, 1986; Vol. 18, p. 341 and references there~ The 13C NMR spectra of the alternative isomers were calculated using the 1.1 Demo version of ACD/CNMR database (Advanced Chemistry Development Inc., Toronto). Ref. 17, pp 131; 152. Sano, H.; Mio, S.; Kitagawa, J.; Shindou, M.; Honma, T.; Sugai, S. Tetrahedron 1995, 51, 12563-12572. Fischer, E. H.; Kxebs, E. G. Meth. Enzymol. 1962, 5, 369-372. Cohen, P. Meth. Enzymol. 1983, 99, 243-250. G-ergely,P.; T6th, B.; Dombrkdi, V.; Matk6, J.; Bot, G. Biochem. Biophys. Res. Commun. 1983, 113, 825-831. Farkas, I.; T6th, B.; Gergely, P.; Bot, G. Acta Biochim. Biophys. Hung. 1987, 22, 17-29. Papageorgiou, A. C.; Oikonomakos, N. G4 Leonidas, D. D.; Bemet, B.; Beer, D.; VaseUa, A. Biochem. J. 1991, 274, 329-338. Stalmans, W.; Hers, H. G.; Eur. J. Biochem. 1975, 54, 341-350. Leatherbarrow, R. J.; Enfitter, A. Non-Linear Regression Data Analysis Program for the IBM-PC Elsevier Biosoft: Cambridge, U.IC, 1987. Segel, I. H. Enzyme Kinetics. Wiley Interscience: New York, 1975; pp 465-504. Gregoriou, M.; Noble, M. E. M.; Watson, K. A.; Garman, E. F.; Krtille, T. M.; de la Fuente, C.; Fleet, G. W. J.; Oikonomakos, N. G.; Johnson, L. N. Protein Sci. 1998, 7, 915-927.

